Fibromyalgia pp 215-235 | Cite as

Fibromyalgia and Pregnancy

  • Dawn A. MarcusEmail author
  • Atul Deodhar

Key Chapter Points

  • Fibromyalgia symptoms tend to worsen with menstrual periods, pregnancy, and delivery.

  • Pregnancy outcome is unaffected by a fibromyalgia diagnosis.

  • Pre-conception discussions should be a routine part of the care of fibromyalgia patients of childbearing potential.

  • Nausea should be treated aggressively during pregnancy to avoid dehydration and poor nutrition.

  • Non-drug treatments should be maximized during pregnancy and when nursing, with medications reserved for more disabling and recalcitrant symptoms.


Breastfeeding Delivery Nursing Pregnancy Post-partum 


  1. 1.
    Ostensen M, Rugelsjøen A. Wigers Sh. The effect of reproductive events and alterations of sex hormone levels on the symptoms of fibromyalgia. Scand J Rheumatol. 1997;26:355–60.PubMedCrossRefGoogle Scholar
  2. 2.
    Schaefer KM. Breastfeeding in chronic illness: the voices of women with fibromyalgia. MCN Am J Matern Child Nurs. 2004;29:248–53.PubMedCrossRefGoogle Scholar
  3. 3.
    Raphael KG, Marbach JJ. Comorbid fibromyalgia accounts for reduced fecundity in women with myofascial face pain. Clin J Pain. 2000;16:29–36.PubMedCrossRefGoogle Scholar
  4. 4.
    Schaefer KM, Black K. Fibromyalgia and pregnancy. What nurses need to know and do. AWHONN Lifelines. 2005;9:228–35.CrossRefGoogle Scholar
  5. 5.
    Marcus DA, Scharff L, Turk DC. Nonpharmacological management of headaches during pregnancy. Psychosom Med. 1995;57:527–35.PubMedGoogle Scholar
  6. 6.
    Scharff L, Marcus DA, Turk DC. Maintenance of effects in the nonmedical treatment of headaches during pregnancy. Headache. 1996;36:285–90.PubMedCrossRefGoogle Scholar
  7. 7.
    American College of Obstetricians and Gynecologists. Exercise during pregnancy and the postpartum period: Technical Bulletin 267. Washington, DC: ACOG Press, 2002.Google Scholar
  8. 8.
  9. 9.
    Juhl M, Kogevinas M, Andersen PK, Andersen AM, Olsen J. Is swimming during pregnancy a safe exercise? Epidemiology. 2010;21:253–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Barakat R, Ruiz JR, Stirling JR, Zakynthinaki M, Lucia A. Type of delivery is not affected by light resistance and toning exercise training during pregnancy: a randomized controlled trial. Am J Obstet Gynecol. 2009;201:590.PubMedCrossRefGoogle Scholar
  11. 11.
    Barakat R, Lucia A, Ruiz JR. Resistance exercise training during pregnancy and newborn's birth size: a randomised controlled trial. Int J Obes. 2009;33:1048–57.CrossRefGoogle Scholar
  12. 12.
    Montgomery KS. Nutrition column an update on water needs during pregnancy and beyond. J Perinat Educ. 2002;11:40–2.PubMedGoogle Scholar
  13. 13.
    Kalichman L. Massage therapy for fibromyalgia symptoms. Rheumatol Int. 2010;30:1151–7.Google Scholar
  14. 14.
    Hedman C, Pohjasvaara T, Tolonen U, Suhonen-Malm AS, Myllylä VV: Effects of pregnancy on mothers’ sleep. Sleep Med. 2002;3:37–42.PubMedCrossRefGoogle Scholar
  15. 15.
    Smith CA, Cochrane S. Does acupuncture have a place as an adjunct treatment during pregnancy? A review of randomized controlled trials and systematic reviews. Birth. 2009;36:246–53.PubMedCrossRefGoogle Scholar
  16. 16.
    Uhl K, Kennedy DL, Kweder SL. Risk management strategies in the Physicians’ Desk Reference product labels for pregnancy category X drugs. Drug Saf. 2002;25:885–92.PubMedCrossRefGoogle Scholar
  17. 17.
    Lo WY, Firedman JM. Teratogenicity of recently introduced medications in human pregnancy. Obstet Gynecol. 2002;100:465–73.PubMedCrossRefGoogle Scholar
  18. 18.
    Addis A, Sharabi S, Bonati M. Risk classification systems for drug use during pregnancy. Are they a reliable source of information? Drug Saf. 2000;23:245–53.PubMedCrossRefGoogle Scholar
  19. 19.
    Streissguth AP, Treder RP, Barr HM, et al. Aspirin and acetaminophen use by pregnant women and subsequent child IQ and attention decrements. Teratology. 1987;35:211–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Li DK, Liu L, Odouli R. Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study. BMJ. 2003;327:368.PubMedCrossRefGoogle Scholar
  21. 21.
    Evers S, Áfra J, Frese A, et al. EFNS guideline on the drug treatment of migraine – report of an EFNS task force. Eur J Neurol. 2006;13:560–72.PubMedCrossRefGoogle Scholar
  22. 22.
    Kozer E, Nikfar S, Costei A, et al. Aspirin consumption during the first trimester of pregnancy and congenital anomalies: a meta-analysis. Am J Obstet Gynecol. 2002;187:1623–30.PubMedCrossRefGoogle Scholar
  23. 23.
    Nørgard B, Puhé E, Caeizel AE, Skriver MV, Sørensen HT. Aspirin use during early pregnancy and the risk of congenital abnormalities: a population-based case-control study. Am J Obstet Gynecol. 2005;192:922–3.PubMedCrossRefGoogle Scholar
  24. 24.
    Klebanoff MA, Berendes HW. Aspirin exposure during the first 20 weeks of gestation and IQ at four years of age. Teratology. 1988;37:249–55.PubMedCrossRefGoogle Scholar
  25. 25.
    Bracken MB, Holfod TR. Exposure to prescribed drugs in pregnancy and association with congenital malformations. Obstet Gynecol. 1981;58:336–44.PubMedGoogle Scholar
  26. 26.
    Saxén I. Epidemiology of cleft lip and palate. An attempt to rule out chance correlations. Br J Prev Soc Med. 1875;29:103–10.Google Scholar
  27. 27.
    Saxén I. Associations between oral clefts and drugs taken during pregnancy. Int J Epidemilol. 1975;4:37–44.CrossRefGoogle Scholar
  28. 28.
    Beers MH, Berkow R, eds. Drug use and dependence. The Merck Manual of Diagnostics and Therapeutics, 17th ed., Section 15, Chapter 195. (Available at Accessed September 30, 2007).
  29. 29.
    Cole JA, Ephross SA, Cosmatos JS, Walker AM. Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf. 2007;16:1075–85.PubMedCrossRefGoogle Scholar
  30. 30.
    Bérard A, Ramos E, Rey E, et al. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol. 2007;80:18–27.PubMedCrossRefGoogle Scholar
  31. 31.
    Einarson A, Choi J, Einarson TR, Koren G. Incidence of major malformations in infants following antidepressant exposure in pregnancy: results of a large prospective cohort study. Can J Psychiatry. 2009;54:242–6.PubMedGoogle Scholar
  32. 32.
    Hemels ME, Einarson A, Koren G, Lanctot KL, Einarson TR. Antidepressant use during pregnancy and the rates of spontaneous abortions: a meta-analysis. Ann Pharmacother. 2005;39:803–9.PubMedCrossRefGoogle Scholar
  33. 33.
    Broy P, Bérard A. Gestational exposure to antidepressants and the risk of spontaneous abortion: a review. Curr Drug Deliv. 2010;7:76–92.Google Scholar
  34. 34.
    Oberlander TF, Warburton W, Misri A, Aghajanian J, Hertzman C. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry. 2006;63:898–906.PubMedCrossRefGoogle Scholar
  35. 35.
    Tuccori M, Testi A, Antonioli L, et al. Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic/noradrenergic antidepressants during pregnancy: a review. Clin Ther. 2009;31:1426–53.PubMedCrossRefGoogle Scholar
  36. 36.
    Briggs GG, Ambrose PJ, Ilett KF, et al. Use of duloxetine in pregnancy and lactation. Ann Pharmacother. 2009;43:1898–902.PubMedCrossRefGoogle Scholar
  37. 37.
    Oberlander TF, Gingrich JA, Ansorge MS. Sustained neurobehavioral effects of exposure to SSRI antidepressants during development: molecular to clinical evidence. Clin Pharmacol Ther. 2009;86:672–7.PubMedCrossRefGoogle Scholar
  38. 38.
    Moses-Kolko EL, Bogen D, Perel J, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA. 2005;293:2372–83.PubMedCrossRefGoogle Scholar
  39. 39.
    Davis RL, Rubanowice D, McPhillips H, et al. Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidemiol Drug Saf. 2007;16:1086–94.PubMedCrossRefGoogle Scholar
  40. 40.
    Warburton W, Hertzman C, Oberlander TF. A register study of the impact of stopping third trimester selective serotonin reuptake inhibitor exposure on neonatal health. Acta Psychiatr Scand. 2010;121:471–9.Google Scholar
  41. 41.
    Pennell PB. Antiepileptic drugs during pregnancy: what is known and which AEDs seem to be safest? Epilepsia. 2008;49:43–55.PubMedCrossRefGoogle Scholar
  42. 42.
    Ohman I, Vitols S, Tomson T. Pharmacokinetics of gabapentin during delivery, in the neonatal period, and lactation: does a fetal accumulation occur during pregnancy? Epilepsia. 2005;46:1621–4.PubMedCrossRefGoogle Scholar
  43. 43.
    Montouris G. Gabapentin exposure in human pregnancy: results from the Gabapentin Pregnancy Registry. Epilepsy Behav. 2003;4:310–7.PubMedCrossRefGoogle Scholar
  44. 44.
    UK National Teratology Information Service September 2007 report. Accessed January 2010.
  45. 45.
    Montouris G. Gabapentin exposure in human pregnancy: results from the Gabapentin Pregnancy Registry. Epilepsy Behav. 2003;4:310–7.PubMedCrossRefGoogle Scholar
  46. 46.
    Almgren M, Källén B, Lavebratt C. Population-based study of antiepileptic drug exposure in utero – influence on head circumference in newborns. Seizure. 2009;18:672–5.PubMedCrossRefGoogle Scholar
  47. 47.
    Power ML, Milligan LA, Schulkin J. Managing nausea and vomiting of pregnancy: a survey of obstetrician-gynecologists. J Reprod Med. 2007;52:922–8.PubMedGoogle Scholar
  48. 48.
    Kennedy KI. Post-partum contraception. Bailleres Clin Obste Gynaecol. 1996;10:25–41.CrossRefGoogle Scholar
  49. 49.
    American Academy of Pediatric Committee on Drugs. The transfer of drugs and other chemicals into human milk. Pediatrics. 2001;108:776–89.Google Scholar
  50. 50.
    Risser A, Donovan D, Heintzman J, Page T. NSAID prescribing precautions. Am Fam Physician. 2009;80:1371–8.PubMedGoogle Scholar
  51. 51.
    Madadi P, Ross CJ, Hayden MR, et al. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. Clin Pharmacol Ther. 2009;85:31–5.PubMedCrossRefGoogle Scholar
  52. 52.
    Davies NM. Clinical pharmacokinetics of ibuprofen. The first 30 years. Clin Pharmacokinet. 1998;34:101–54.PubMedCrossRefGoogle Scholar
  53. 53.
    Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder SJ. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet. 2006;368:704.PubMedCrossRefGoogle Scholar
  54. 54.
    Gaedigk A, Ndjontché L, Divakaran K, et al. Cytochrome P4502D6 (CYP2D6) gene locus heterogeneity: characterization of gene duplication events. Clin Pharmacol Ther. 2007;81:242–51.PubMedCrossRefGoogle Scholar
  55. 55.
    Wojnar-Horton RE, Hackett LP, Yapp P, et al. Distribution and excretion of sumatriptan in human milk. Br J Clin Pharmacol. 1996;41:217–21.PubMedCrossRefGoogle Scholar
  56. 56.
    Lobo ED, Loghin C, Knadler MP. Pharmacokinetics of duloxetine in breast milk and plasma of healthy postpartum women. Clin Pharmacokinet. 2008;47:103–9.PubMedCrossRefGoogle Scholar
  57. 57.
    Academy of Breastfeeding Medicine Protocol Committee. ABM clinical protocol #18: use of antidepressants in nursing mothers. Breastfeed Med. 2008;3:44–52.CrossRefGoogle Scholar
  58. 58.
    Kristensen JH, Ilett KF, Hackett LP, Kohan R. Gabapentin and breastfeeding: a case reports. J Hum Lact. 2006;22:426–8.PubMedCrossRefGoogle Scholar
  59. 59.
    Ip S, Chung M, Raman G, et al. Breastfeeding and maternal and infant health outcomes in developed countries. Evid Rep Technol Assess (Full Rep). 2007;135:1–186.Google Scholar
  60. 60.
    Pikwer M, Bergström U, Nilsson JA, et al. Breast-feeding, but not oral contraceptives, is associated with a reduced risk of rheumatoid arthritis. Ann Rheum Dis. 2009;68:526–30.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Department of AnesthesiologyUniversity of PittsburghPittsburghUSA
  2. 2.Division of Arthritis & Rheumatic Diseases (OP09)Oregon Health and Science UniversityPortlandUSA

Personalised recommendations